clinical trial · NCT05890742
A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer
Innovent Biologics (Suzhou) Co. Ltd.·phase3·recruiting·n = 360
MSI-HSintilimabIBI310&SintilimabRadical surgery
brief summary
Evaluate efficacy and safety of IBI310 (CTLA-4 antibody) in combination with Sintilimab, for neoadjuvant treatment of MSI-H/dMMR resectable colon cancer
started
May 25, 2023
primary completion
Apr 15, 2028
completion
Jul 15, 2028
last updated
Mar 15, 2024
official title
A Phase 1b/3 Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol